Article
Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network.
Molecular cancer therapeutics - 1 May 2017
Chatterjee Suman, Huang Eric H-B, Christie Ian, Kurland Brenda F, Burns Timothy F
Abstract excerpt
Approximately 25% of non-small cell lung cancer (NSCLC) patients have KRAS mutations, and no effective therapeutic strategy exists for these patients. The use of Hsp90 inhibitors in KRAS-mutant NSCLC appeared to be a promising approach, as these inhibitors target many KRAS downstream effectors; however, limited clinical efficacy has been observed due to resistance. Here, we examined the mechanism(s) of acquired...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.